Use and abuse of the benzodiazepines

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 481-489

  Fraser, Albert D ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Abuse; Adverse effects; Benzodiazepines; Poisoning; Use

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BROMAZEPAM; BROTIZOLAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM; NITRAZEPAM; OXAZEPAM; PRAZEPAM; TEMAZEPAM; TRIAZOLAM;

AMNESIA; ANXIETY NEUROSIS; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG ABUSE; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; EPILEPSY; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SEIZURE;

ANTI-ANXIETY AGENTS; BENZODIAZEPINES; DRUG MONITORING; DRUG UTILIZATION; HUMANS; OVERDOSE; SUBSTANCE-RELATED DISORDERS; WORLD HEALTH;

EID: 0031685608     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00007     Document Type: Conference Paper

References (78)

1. Beaumont G. The use of benzodiazepines in general practice. In: Hindmarch I, ed. Benzodiazepines: Current Concepts. Chichester: John Wiley & Sons; 1990:141-52.
2. Lader M. History of benzodiazepine dependence. J Subst Abuse Treat 1991;8:53-9.
3. Taylor D. Current usage of henzodiazepines in Britain. In: Freeman H, Rue Y, eds. The Benzodiazepines in Current Clinical Practice. London: Royal Society of Medicine Services; 1987:13-8.
4. Crook TH, Kupfer DJ, Hoch CC, et al. Treatment of sleep disorders in the elderly. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987: 1159-65.
5. Gillin JC. The long and short of sleeping pills. N Engl J Med 1991;324:1735-7.
6. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatr 1985;42:225-32.
7. Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Curr Probl 1988:21.
8. Ashton H. Guidelines for the rational use of benzodiazepines. Drugs 1994;48:25-40.
9. Lader M. Long-term benzodiazepine use and psychological functioning. In: Freeman H, Rue Y, eds. The Benzodiazepines in Current Clinical Practice. International Congress and Symposium Series. London: Royal Society of Medicine Services; 1987:55-69.
10. Lader MH, Petursson H. Benzodiazepine derivatives - side effects and dangers. Biol Psychiatr 1981;16:1195-212.
11. Marriott S, Tyrer P. Benzodiazepine dependence: avoidance and withdrawal. Drug Saf 1993;9:93-103.
12. Murphy SB, Tyrer P. The essence of benzodiazepine dependence. In: Lader M, ed. Psychopharmacology and Addiction. Oxford: Oxford University Press; 1988:157-67.
13. Tyrer P. Risks of dependence on benzodiazepine drugs: the importance of patient selection. Br Med J 1989;298:102-5.
14. Brodie MJ. Status epilepticus in adults. Br Med J 1990;336:551-2.
15. Trimble MR. Benzodiazepines in clinical practice. In: Wheatley D, ed. The Anxiolytic Jungle: Where Next? Chichester: John Wiley & Sons; 1990: 9-21.
16. Feely M. Clonazepam and clobazam. Prescribers J 1989;29: 111-5.
17. International Narcotics Control Board. Treaty Series 976, No. 14152. Vienna: United Nations. 1972.
18. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics for 1995: Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations; Sales No. E/F/S.97.XI.2. 1997.
19. International Narcotics Control Board. New York: United Nations; Sales No. E.96.XI.3, 1995;197:205.
20. International Narcotics Control Board. New York: United Nations; Sales No. E.97.XI.3. 1996:217
21. International Narcotics Control Board. New York: United Nations; Sales No. E.97.XI.3, 1996:346.
22. International Narcotics Control Board. Technical Report: Psychotropic Substances-Statistics, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:67-68.
23. International Narcotics Control Board. Technical Report: Psychotropic Substances-Statistics, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:69.
24. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:92-9.
25. Bergman U, Grimsson A, Wahba AHW, Westerholm B, eds. Studies in drug utilization: methods and applications. Copenhagen: World Health Organization; 1979:8.
26. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:116-21.
27. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics for 1995, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:200.
28. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics for 1995: Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:200.
29. International Narcotics Control Board. Technical Report: Psychotropic Substances - Statistics for 1995, Assessments of Medical and Scientific Requirements for Substances in Schedules II, III and IV. New York: United Nations, Sales No. E/F/S.97.XI.2; 1995:203-3.
30. The top 200 drugs of 1996. Pharm Pract 1996;12:67-79.
31. The top 200 drugs. Am Druggist 1997;210:30-7.
32. Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD. Relative abuse liability of diazepam and oxazepam: behavioural and subjective dose effects. Psychopharmacology 1984;84:147-54.
33. Bond A, Silveira JC, Lader M. Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum Psychopharmacol 1991;6:219-28.
34. Perera KMH, Tulley M, Jenner FA. The use of benzodiazepines among drug addicts. Br J Addict 1987;82:511-15.
35. Launchbury AP, Drake J, Seager H. Misuse of temazepam. Br Med J 1992;305:252-3.
36. Barnas C, Rossman M, Roessler H, Reimer Y, Fleishaker WW. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992;12:397-402.
37. Livingston MG. Benzodiazepine dependence: avoidance, detection and management. Prescribes J 1991;31:149-56.
38. Piper A. Addiction to benzodiazepines - how common. Arch Fam Med 1995;4:964-70.
39. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacologv 1995;118:107-15.
40. Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines: issues relevant to prescribing. JAMA 1988;260:3476-80.
41. Miller NS, Gold MS. Introduction - benzodiazepines: a major problem. J Subst Abuse Treat 1991;8:3-7.
42. Griffiths RR. Commentary on review by Woods and Winger. Psychopharmacology 1995;118:116-7.
43. Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10:237-43.
44. Troisi JR II, Critchfield TS, Griffiths RR. Buspirone and lorazepam abuse liability in humans: behavioural effects, subjective effects and choice. Behav Pharmacol 1993;4:217-30.
45. Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatr 1993;54:64-75.
46. Bond A, Seijas D, Dawling S, Lader M. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994;89:821-30.
47. Darke S, Swift W, Hall W, Ross M. Drug use, HIV risk taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend 1994;34:67-70.
48. Ruben SM, Morrison CL. Temazepam misuse in a group of injecting drug users. Br J Addict 1992;87:1387-92.
49. Darke SG, Ross JE, Hall WE. Benzodiazepine use among injecting heroin users. Med J Aust 1995;162:645-47.
50. Rush CR, Higgins WK, Bickel WK, Hughes JR. Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. Neurosci Biobehav Rev 1993;17:277-85.
51. Gallaher EJ, Jacques CJ, Hollister LE. Alprazolam dependence in mice. Alcohol Drug Res 1987;7:503-10.
52. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Ann Rev Pharmacol Toxicol 1987;39:251-413.
53. Rickels K, Schweizer E, Case G. Long term therapeutic use of benzodiazepines, I: effects of abrupt discontinuation. Arch Gen Psychiatr 1990;47:899-907.
54. Prescott LP, Highly MS. Drugs prescribed for self poisoners. Br Med J 1985;290:1633-6.
55. Ekedahl AM, Lowenhielm P, Nimeus A, Regnell G, Traskman -Bendz L. Medicine self-poisoning and the sources of the drugs in Lund, Sweden. Acta Psychiatr Scand 1994;89:255-61.
56. Kales A, Kales JD, Bixler EO, Scharf M, Russek E. Hypnotic efficacy of triazolam: sleep laboratory evaluation of intermediateterm effectiveness. J Clin Pharmacol 1976;16:399-406.
57. Morgan K, Oswald I. Anxiety caused by a short half life hypnotic. Br Med J 1982;284:942.
58. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Science 1978;201:1039-41.
59. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial III: discontinuation effects. Arch Gen Psychiatr 1988;45:429-36.
60. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995;51:205-23.
61. Soderpalm B. Pharmacology of the benzodiazepines with special emphasis on alprazolam. Acta Psychiatr Scand 1987;76(suppl 335):S39-46.
62. Finkle BS, McCloskey KL, Goodman LS. Diazepam and drug associated deaths: a survey in the United States and Canada. JAMA 1979;242:429-34.
63. Brødsgaard I, Hansen C, Vesterby A. Two cases of lethal nitrazepam poisoning. Am J Forens Med Pathol 1995;16:151-53.
64. Robertson MD. Deaths involving flunitrazepam: an Australian experience. J Anal Toxicol 1997;21:81.
65. Sunter JP, Bal TS, Cowan WK. Three cases of fatal triazolam poisoning. Br Med J 1988;297:719.
66. Joynt BP. Triazolam blood concentrations in forensic cases in Canada. J Anal Toxicol 1993;17:171-7.
67. Jenkins AJ, Levine B, Laron Locke J, Smialek JE. A fatality due to alprazolam intoxication. J Anal Toxicol 1997;21:218-20.
68. McIntyre IM, Syrjanen ML, Lawrence KL, Dow CA, Drummer OH. A fatality due to flurazepam. J Forensic Sci 1994;39:1571-4.
69. Uemura K, Komura S. Death caused by triazolam and ethanol. Am J Forens Med Pathol 1995;16:66-8.
70. Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatr 1993;163:386-93.
71. Brahams D. Triazolam licensing in UK. Lancet 1993;341:1587.
72. Dyer C. New report criticises Upjohn over Halcion. Br Med J 1994;308:1321-2.
73. Brahams D. Triazolam suspended. Lancet 1991;338:938.
74. New Halcion labeling. FDA Med Bull 1992;22:7-8.
75. Lasagna L, Shader RI. A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics. J Clin Pharmacol 1994;34:812-15.
76. Nazareth I, Ashworth M, Hammond J, King M. Withdrawal of triazolam's product licence: effect on patients 18 months later. Addiction 1995;90:927-34.
77. Top 200 drugs. Am Druggist 1993:47-58.
78. Top 200 drugs. Pharm Practice 1992;8:27-34.